Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its primary endpoint, the study confirmed that TAK-279 improved symptoms significantly better than a placebo at 12 weeks. This news supports TAK-279’s potential as a robust oral treatment for psoriatic arthritis […]